Inhibikase Therapeutics (IKT) Gains from Investment Securities (2020 - 2021)
Inhibikase Therapeutics (IKT) posted quarterly Gains from Investment Securities of $29839.0 for Q4 2021, up 109.75% year-over-year from $14226.1 in Q4 2020, and down 83.58% quarter-over-quarter from $181762.0 in Q3 2021.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Gains from Investment Securities (2020 - 2021) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Gains from Investment Securities for 2 consecutive years, with $29839.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Gains from Investment Securities rose 109.75% year-over-year to $29839.0; the TTM figure through Sep 2022 stood at $29839.0 (down 91.54% YoY), while the FY2021 annual figure was $688784.0, up 226.67% from the prior year.
- Gains from Investment Securities slipped to $29839.0 in Q4 2021 per IKT's latest filing, from $181762.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $239415.0 in Q2 2021 and bottomed at -$306075.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 29,839.00 |
| Sep 30, 2021 | 181,762.00 |
| Jun 30, 2021 | 239,415.00 |
| Mar 31, 2021 | 237,768.00 |
| Dec 31, 2020 | 926,503.00 |
| Sep 30, 2020 | 236,415.00 |
| Jun 30, 2020 | 89,515.00 |
| Mar 31, 2020 | 190,993.00 |